Krka, d.d., Novo mesto (hereafter referred to as Krka) is informing the public that AstraZeneca AB, Sweden and AstraZeneca UK Limited have not applied for leave to appeal at the Supreme Court against the decision of the Court of Appeal which awarded to Krka damages and legal costs in the amount of slightly less than EUR 21 million for losses Krka had suffered because it was injuncted to sell its esomeprazole products in the Great Britain between mid-2010 to mid-2011 because alleged infringement of the patent EP 1 020 461.

Krka will reverse the provisions formed for the esomeprazole case in the amount of EUR 20 million as all legal means have been exhausted. The reversal of provisions will be recognized in the 2015 financial statements.

Krka published the announcements considering esomeprazole litigation in the Great Britain on 7 April 2014 and 22 May 2015.